MEDFORD, N.Y. , March 03, 2020 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, is providing an update on the FDA Premarket Approval (PMA) application for Chembio’s DPP HIV-Syphilis Assay System.
MEDFORD, N.Y. , Feb. 12, 2020 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced a $1.5 million purchase order from UNICEF for multiplex Zika tests and Micro Readers following the successful
MEDFORD, N.Y. , Jan. 09, 2020 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced President and Chief Executive Officer John Sperzel has resigned for another opportunity.
Anticipates FDA Approval of Multiplex Test and Micro Reader During Q1 2020 MEDFORD, N.Y. , Jan. 02, 2020 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today provided an update on its Premarket Approval
MEDFORD, N.Y. , Nov. 25, 2019 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced that it has completed its previously announced acquisition of Orangelife Comercio e Industria Ltda., a Brazilian
MEDFORD, N.Y. , Nov. 14, 2019 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today the company plans to participate in two upcoming investor conferences.
MEDFORD, N.Y. , Nov. 07, 2019 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today reported financial results for the quarter ended September 30, 2019 . Recent Accomplishments & Highlights Achieved total
Acquisition will expand commercial presence and market opportunity in Brazil MEDFORD, N.Y. , Nov. 07, 2019 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced that it has entered into a definitive
Innovative HIV Self-Test Uses the World’s Smallest Blood Sample MEDFORD, N.Y. , Nov. 04, 2019 (GLOBE NEWSWIRE) -- November 4, 2019 - Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced its SURE CHECK HIV Self-Test has
MEDFORD, NY , Oct. 24, 2019 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today that it will release financial results for the third quarter of 2019 after the close of trading on Thursday, November
Print Page